Comparative Economic Analysis of Retreatment Strategies for HCV Genotype 1 Patients in Russia

• DOI: 10.1016/j.jval.2013.08.1120
• Publication Date: 2013-10-22T07:52:28Z
• Authors: O. Ivakhnenko; V.V. Omelyanovsky; O. Rebrova; G. Khachatryan
• Keywords: Boceprevir; Incremental cost-effectiveness ratio; Reimbursement; Pegylated interferon; Hepatitis C

To assess the cost-effectiveness of retreatment with pegylated interferon and ribavirin in combination boceprevir HCV genotype 1 patients, who failed to respond previous treatment, comparison absence ribavirin. We performed analysis. Based on published data we modeled number long-term unfavorable outcomes (liver cirrhosis, hepatocellular carcinoma death) hypothetic cohort patients following one three strategies: “no treatment” (NT), “peginterferon+ribavirin” (PR) “peginterferon + boceprevir” (PRB). have evaluated direct medical costs for a short-term (only cost retreament) (costs care adverse outcomes) periods all strategies. Costs were estimated basis average price drugs reimbursement rates services compulsory insurance system. Incremental ratio (ICER) PR PRB strategies vs NT calculated as additional per outcome avoided. It is expected that 10000 58,1% would fail treatment. The this group EURO 69,07 mln case strategy 235,58 PRB. cumulative during 25-year period be 5075 cases strategy, 4262 2012 205,35 mln, 168,37 81,4 ICER was 44532 - 36379 use efficient it allows reducing at lesser cost.